Company profile
Fortress Biotech, Inc.
NASDAQ: FBIO · Healthcare · Biotechnology
#409 of 1,418 Healthcare companies by revenue57th-percentile growth
EA Score
62CFH 72DQ 51GM 55SS 62
v0.1 · 65/100 weight · provisional
↑ net margin, Piotroski F · ↓ filing timeliness, 3-yr revenue growth
Methodology →Revenue TTM
$66.2M
Rev growth YoY (TTM)
+14.5%
Net income (FY)
$6.8M
Employees
78
as of 2026-08-18
Market cap
$93.3M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$61.2M$61.2M2025
Net income$6.8M$6.8M2025
Operating income-$70.2M-$70.2M2025
Total assets$185.5M$185.5M2025
Liabilities$123.4M$123.4M2025
Equity$49.9M$49.9M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2024
By product
Qbrexza49%
Accutane38%
Amzeeq10%
Zilxi3%
By geography
Not disclosed.
The read
What is Fortress Biotech, Inc.’s revenue?
Fortress Biotech, Inc. booked $61.2M in FY2025 revenue, growing 11% year over year — about the middle of the pack among Healthcare companies we track, at a 11.1% net margin.
Peers · Healthcare
Sorrento Therapeutics, Inc.——Tango Therapeutics, Inc.55CJourney Medical Corporation52DKestra Medical Technologies, Ltd.——Etao International Co., Ltd.——Flower One Holdings Inc.——Neighbors
Miami-Dade →Key facts
CEOLindsay Allan Rosenwald
SectorHealthcare
IndustryBiotechnology
HeadquartersBay Harbor Islands, FL
ExchangeNASDAQ: FBIO
Employees78
IPO date2011-11-17
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.